New funding to take Vital's liver failure cell therapy through Phase III
This article was originally published in Scrip
Vital Therapies closed the first $16 million from a $76 million funding commitment from its existing private investors to finance three pivotal Phase III clinical trials for the company's human allogeneic cellular therapy developed to treat acute liver failure.
You may also be interested in...
A number of pivotal studies are expected to report top-line data in the third quarter. Here, with the help of Informa Pharma's Biomedtracker, we take a look at eight of those likely to be major catalysts for their sponsors.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.